PYXSHIGH SIGNALRISK10-K

PYXS added explicit "substantial doubt about our ability to continue as a going concern" language while burning through cash with stockholders' equity declining 55.8% to $53.4M.

The addition of going concern doubt language represents a material escalation in management's assessment of the company's financial viability, signaling immediate liquidity concerns that could threaten operations. Combined with accelerating cash burn and shrinking financial cushion, investors face heightened risk of dilutive equity raises or potential business failure if adequate funding cannot be secured.

Comparing 2026-03-23 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

PYXS shows clear financial deterioration with stockholders' equity collapsing 55.8% to $53.4M, total assets declining 41.8%, and operating cash flow worsening to -$63.5M despite revenue of $13.9M. The company increased R&D spending 25.4% to $73.7M while current liabilities grew 19.5%, creating a dangerous combination of accelerating burn rate and diminishing financial resources. This financial profile supports management's new going concern warnings and signals urgent need for capital infusion.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-96.2%
$237K$9K

Capex reduced 96.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-55.8%
$120.8M$53.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-45.6%
$132.4M$72.1M

Current assets declined 45.6% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-41.8%
$157.2M$91.5M

Total assets contracted 41.8% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
+25.4%
$58.7M$73.7M

R&D investment increased 25.4% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
-20.8%
$19.5M$15.4M

Cash decreased 20.8% — monitor burn rate and upcoming capital needs.

Current Liabilities
Balance Sheet
+19.5%
$17.7M$21.1M

Current liabilities rose 19.5% — increased short-term obligations, watch current ratio.

Revenue
P&L
-14.2%
$16.1M$13.9M

Revenue softened 14.2% — monitor whether this is cyclical or structural.

Operating Cash Flow
Cash Flow
-10.1%
-$57.7M-$63.5M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-18
ADDED
As of March 20, 2026, the Registra nt had 62,831,246 shares of common stock, $0.00 1 par value per share, outstanding.
We have substantial doubt about our ability to continue as a going concern and we will require substantial additional capital to finance our operations.
If we are unable to raise such capital when needed, or on acceptable terms, we may not be able to continue as a going concern or we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.
Overview Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC).
Our lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational novel antibody-drug conjugate (ADC) that uniquely targets the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the extracellular matrix (ECM) in the tumor microenvironment (TME).
+7 more — sign up free →
REMOVED
As of March 17, 2025 , the Registrant had 61,590,415 shares of common stock, $0.001 par value per share, outstanding.
We will require substantial additional capital to finance our operations.
If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts.
Overview Pyxis Oncology is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC) tumors.
Our lead product candidate, micvotabart pelidotin, formerly referred to as PYX-201, is an investigational novel antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extra-cellular matrix (ECM).
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →